Review: selective COX 2 inhibitors increase vascular events more than placebo and naproxen but not more than other NSAIDs

@article{Laupacis2006ReviewSC,
  title={Review: selective COX 2 inhibitors increase vascular events more than placebo and naproxen but not more than other NSAIDs},
  author={Andreas Laupacis},
  journal={Evidence Based Medicine},
  year={2006},
  volume={11},
  pages={171 - 171}
}
  • A. Laupacis
  • Published 30 November 2006
  • Medicine
  • Evidence Based Medicine
MAIN RESULTS Selective COX 2 inhibitors increased risk of all vascular events and MI, but not stroke (table) or vascular death, more than placebo and naproxen. COX 2 inhibitors and non-naproxen NSAIDs did not differ for all vascular events, MI (table), or vascular death. Risk of stroke was lower with COX 2 inhibitors (table). When data from indirect and direct comparisons were used, the rate ratios for all vascular events of traditional NSAIDs compared with placebo were 0.9 (95% CI 0.7 to 1.3… 
View on BMJ
acpjc.org
2 Citations

2 Citations

Citation Type

Citation Type

Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials
TLDR
Selective COX 2 inhibitors are associated with a moderate increase in the risk of vascular events, as are high dose regimens of ibuprofen and diclofenac, but high dose naproxen is not associated with such an excess.
Decoction of heat-clearing, detoxifying and blood stasis removing relieves acute soft tissue injury via modulating miR-26b-5p/COX2 axis to inhibit inflammation
TLDR
It is revealed that HDBD relieved acute STI via modulating miR-26b-5p/COX2 axis to inhibit inflammation through the effect and mechanism of heat-clearing, detoxifying and blood stasis removing decoction.

References

352:1081-91. Risk for vascular events with selective cyclooxygenase-2 (COX-2) inhibitors vs placebo, naproxen, or other traditional nonsteroidal antiinflammatory drugs
  • N Engl J Med
  • 2005